IKT News and Press, Inhibikase Therapeutics Inc. From 08/17/23

Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of IkT-001Pro PR Newswire - 600 mg IkT-001Pro demonstrated bioequivalence to Standard-of-Care 400 mg Dose of Imatinib mesylate - - Minimal adverse events with consistent drug delivery see...

2023-08-15 11:14:06 ET Inhibikase Therapeutics, Inc. (IKT) Q2 2023 Earnings Conference Call August 15, 2023 08:00 ET Company Participants Alex Lobo - Investor Relations Milton Werner - Chief Executive Officer Joe Frattaroli - Chief Financial Officer Confere...

2023-08-14 16:34:39 ET Inhibikase Therapeutics press release ( NASDAQ: IKT ): Q2 GAAP EPS of -$1.11 misses by $0.19 . Revenue of $116.41M (+1677.3% Y/Y). For further details see: Inhibikase Therapeutics GAAP EPS of -$1.11 misses by $0.19, revenue of $116.41M

Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity PR Newswire Company to host conference call on Tuesday, August 15, 2023 at 8:00 a.m. ET BOSTON and ATLANTA , Aug. 14, 2023 /PRNewswire/ --&#...

Inhibikase Therapeutics to Report Second Quarter Financial Results on August 14, 2023 PR Newswire BOSTON and ATLANTA , Aug. 7, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical compan...

2023-07-18 06:39:52 ET Clinical-stage pharmaceutical company, Inhibikase Therapeutics, ( NASDAQ: IKT ) receives notice from Nasdaq that it has regained full compliance with the minimum bid price requirement of $1.00 per share. Inhibikase is now in compliance with all appli...

Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements PR Newswire BOSTON and ATLANTA , July 17, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing ...

2023-06-29 09:42:20 ET Inhibikase Therapeutics ( NASDAQ: IKT ) will effect a 1-for-6 reverse stock split that will become effective on June 30, 2023. Inhibikase's common stock will continue to be traded on the Nasdaq Capital Market under the symbol "IKT" and will begin tra...

Inhibikase Therapeutics Announces a 1-for-6 Reverse Stock Split PR Newswire BOSTON and ATLANTA , June 29, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase ...

Inhibikase Therapeutics Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the '501' Bioequivalence Study PR Newswire - 600 mg dose of IkT-001Pro selected as the bioequivalent dose relative to standard of care 400 mg imatinib...